Entrada Therapeutics Inc TRDA.OQ TRDA.O is expected to show a fall in quarterly revenue when it reports results on November 3 (estimated) for the period ending September 30 2025
The Boston Massachusetts-based company is expected to report a 30.0% decrease in revenue to $13.702 million from $19.57 million a year ago, according to the mean estimate from 3 analysts, based on LSEG data.
LSEG's mean analyst estimate for Entrada Therapeutics Inc is for a loss of 94 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Entrada Therapeutics Inc is $18.50, about 62.7% above its last closing price of $6.90
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Jun. 30 2025 | -0.86 | -0.85 | -1.04 | Missed | -22.7 |
Mar. 31 2025 | -0.79 | -0.79 | -0.42 | Beat | 46.8 |
Dec. 31 2024 | -0.67 | -0.67 | 0.03 | Beat | 104.5 |
Sep. 30 2024 | -0.71 | -0.73 | -0.35 | Beat | 51.9 |
Jun. 30 2024 | 0.14 | 0.15 | 1.55 | Beat | 969 |
Mar. 31 2024 | -0.61 | -0.59 | 0.68 | Beat | 214.5 |
Dec. 31 2023 | 0.12 | -0.17 | -0.29 | Missed | -72.6 |
Sep. 30 2023 | -0.76 | -0.74 | 1.02 | Beat | 238.6 |
This summary was machine generated October 31 at 14:39 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Comments